Review Article

A Chinese Prescription Chuanxiong Chatiao San for Migraine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Yu Wang,1 Yajun Shi,1,2 Xiaofei Zhang,1,2 Junbo Zou,1,2 Yulin Liang,1 Jia Tai,1 Mei Wang,1,2 Chunli Cui,1,2 and Dongyan Guo1,2

1Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China
2Key Laboratory of Basic and New Drug Research of Traditional Chinese Medicine, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China

Correspondence should be addressed to Yajun Shi; 2051004@sntcm.edu.cn

Received 12 April 2019; Accepted 13 June 2019; Published 31 July 2019

Academic Editor: Hajime Nakae

Copyright © 2019 Yu Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Backgrounds. Chuanxiong Chatiao san (CXCT) is a famous Chinese classical prescription. It has a favorable effect in treating migraine. It is reported that CXCT combined with Western conventional medicine (WCM) could increase the therapeutic efficacy on migraine. The purpose of this paper is to systematically assess the clinical efficacy, safety, and some indexes of CXCT for migraine.

Methods. PubMed, Embase Database, China National Knowledge Infrastructure (CNKI), Wanfang Database, the Cochrane Library, and the CBM were searched from January 2000 to February 2019. We made a detailed record of outcome measurements. Meta-analysis was performed using RevMan 5.3 software.

Results. A total of 3307 patients were included in the 37 articles. Meta-analysis showed that CXCT significantly increased the total efficiency rate (TER), compared with Western medicine treatment (WMC) (P < 0.00001). When CXCT is combined with WMC, the result showed that P < 0.00001. CXCT was significantly reduced the adverse events (AEs) compared with WMC (P < 0.00001). The levels of VAS, number of migraine episodes (NE), and time of headache duration (TD) were significantly reduced (P < 0.00001). Platelet function and blood rheology level were improved via a significantly decrease in 5-HT and β-EP (P < 0.00001). Other indicators such as substance P, CGRP high-cut viscosity, low-cut viscosity, plasma viscosity, and fibrinogen were significantly reduced (P < 0.00001). Conclusion. Our findings provide evidence that CXCT and CXCT combined with WMC have higher efficacy in the treatment of migraine compared with WCM alone. Methodological quality was generally low, so the conclusion of this paper has some limitations and it has to be carefully evaluated.

1. Background

Migraine is a common disease that occurs repeatedly. It belongs to one kind of neurovascular disease. There is a pulsating pain on one side of the head when a migraine attack, which is often accompanied by nausea, vomiting and blurred vision. Besides, sound and light stimulation will increase the pain [1, 2]. According to incomplete statistics, 3.3% to 32.6% of women and 0.7% to 16.1% of men are affected each year. In 2001, the World Health Organization (WHO) had listed severe migraine, paralysis of limbs, mental disorders and dementia as the most serious chronic dysfunction diseases [3]. Recurrence and stubbornness of migraine have caused serious problems in the normal life of patients, whereas there currently are the limitations of conventional therapies available.

Western medicine often uses painkillers to treat migraine, such as nonspecific analgesics (nonsteroidal anti-inflammatory drugs (NSAID), sedatives, opioids, etc.) [4]. The effective treatment of migraine is limited by the availability, cost and AEs caused by overusing analgesics and antimigraine drugs of conventional Western medicine [5]. It was reported AEs that included gastrointestinal reactions, neurotoxicity and hepatotoxicity, and addiction. Thus, many migraine patients resort to complementary and alternative medicine [6]. So it is significant to find new drugs to treat migraine.
Recently, clinical trials and systematic reviews of increasing numbers showed that, as compared to WCM therapy, Chinese herbal formula has obvious advantages in the prevention and treatment of this disease [7]. Migraine belongs to the category of “intermittent headache”, “facial attack by wind” in traditional Chinese medicine. CXCT is from “Prescriptions People’s Welfare Pharmacy” and it has a history of more than 1000 years for treating migraine. The CXCT consists of eight herbs, *Ligusticum chuanxiong hort.*, *Angelicae Dahuricae Radix*, *Notopterygium incisum Ting ex H. T. Chang*, *Asarum sieboldii Miq.*, *Radix Saposhnikoviae Divaricatae*, *Nepeta cataria L.*, *Mentha haplocalyx Briq.*, and *Glycyrrhiza uralensis Fisch* [8]. Until now, CXCT has been widely applied in the clinical treatment of various headaches and it has very well curative for migraine treatment to reduce the frequency and severity of migraine attacks (Level A) [9–11]. The effectiveness of the main components in CXCT has been proven [12]. CXCT can be used to treat various headaches such as migraine as well as some diseases just like dizziness, cold cough, head pain, and rhinitis [13]. The results of clinical trial indicated that CXCT reduced headache duration and intensity of pain; besides, it could reduce the times of migraine headache and improve quality of life in migraine patients. At the same time, it can significantly inhibit platelet aggregation, improve activation, and release response of platelet and decreases the corresponding indexes of hemorheology [14–16]. By inhibiting the contraction of the vascular smooth muscle, CXCT can enlarge the blood flow in the blood vessel to decrease thrombosis, which has certain improvement on brain damage and is beneficial to treat the blood vessel to decrease thrombosis, which has certain

vascular smooth muscle, CXCT can enlarge the blood flow in the blood vessel to decrease thrombosis, which has certain improvement on brain damage and is beneficial to treat the vascular headache [17]. Therefore, CXCT has a good prospect in the treatment of migraine.

It is crucial to renew the search and appraise to provide the best evidence for migraine. This paper aims to use the principle of evidence-based medicine to conduct meta-analysis and evaluation of clinical efficacy on CXCT for migraine, so as to provide the reference for clinical research and application.

### 2. Methods

#### 2.1. Search Strategies

We searched PubMed, Embase Database, China National Knowledge Infrastructure (CNKI), Wanfang Database, the Cochrane Library, and the CBM (documents collected from January 2000 to February 2019) on the treatment of migraine with Chuanxiong Chatiao san. The language of the text is limited to Chinese and English.

Theme for database searching was “Chuanxiong Chatiao san” [Title or Keywords], “Chuanxiong Chatiao san” AND “Migraine” [Title and Keywords]. Supplement articles were obtained by manual retrieval the references in the article.

And relevant RCTs were downloaded into Endnote software (version X8, Thomson Reuters, Inc., New York, USA) for further exploring. We have made detailed records and analysis of relevant data. Duplicate records were removed. The full-text review was performed, while the title/abstract was thought to be thematic.

#### 2.2. Inclusion and Exclusion Criteria

The literature included meets the following criteria:

1. Migraine patients were diagnosed according to the following criteria: International Headache Society (IHS), The Clinical Guidelines for the New Chinese Medicine (TCGNCM), Clinical Diagnosis Symptoms of Study (CDSS), Standard of TCM Diagnosis and Efficacy (STCMEDE), Practical Neurology (PN), Diagnostic Criteria and Treatment Points of Internal Medical Diseases (DCTPIMEC), Handbook of Clinical Neurology (HCN), Internal Medicine of Traditional Chinese Medicine (IMTCM), or Practical Internal Medicine (PIM).
2. All the substudies were RCTs.
3. In the study A, the experimental group used CXCT Chinese medicine decoction alone and the control group used Western medicine alone or in combination with other drugs.
4. In the study B, the experimental group used CXCT combined with WMC and he control group was treated Western medicine alone.
5. Do not limit the age, gender, race, or other basic conditions of patients.
6. The primary outcome measure was the TER. Effective means that the degree of headache is relieved, and the frequency and duration of headache attacks are reduced. The second outcome measures were AEs and some biological indexes.

The exclusion criteria were as follows:

1. The article was repeatedly published.
2. The type of the article included animal experiment, review, and case report.
3. Besides CXCT and drugs, acupuncture was used in the experiment group.
4. Trails were not RCTs or there were no criteria.
5. This patient was not diagnosed with migraine.
6. The full-text cannot be found.

#### 2.3. Data Extraction and Quality Assessment

This meta-analysis used Review Manager 5.3 software to perform quality assessment. It was evaluated from random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases and divided into three indexes: “high risk,” “unclear risk,” and “low risk.”

Scientific evaluation of the literature is not only beneficial to the improvement of clinical trials, but also has important significance for the merger and analysis of the articles. These data were separately collected and cross-checked by two researchers, and the controversial content or the score of the article was determined by a third person after careful assessment.

Information collected included the author names, year of publication, numbers of cases, methodological characteristics, outcome measures, adverse events, and follow-up records. These data were separately collected and cross-checked by two researchers. The controversial content was determined by a third person after careful assessment.

#### 2.4. Data Analysis

Meta-analysis was using RevMan 5.3 software which published on the Cochrane Collaboration. Heterogeneity was assessed by means of $I^2$ statistic. Fixed-effect model of meta-analysis was used to analyze data that were low heterogeneous. $I^2 > 50\%$ represented high
heterogeneity; random-effect model was used to analyze the data. Outcome measures such as TER and AEs regard as dichotomous variables used the odds ratio (OR) values with 95% confidence interval (95% CI). If outcomes were continuous data, they were presented as weighted mean difference (WMD) and its 95% CI. Funnel plot was used to analyze publication bias.

3. Results

3.1. Characteristics of the Eligible Studies. A total of 875 articles were retrieved in this study, among which 354 were duplicated. After rescreening the titles and abstracts, 521 articles were included. Finally, 280 articles were excluded after checking the full text. Thus, 36 eligible studies were included. Among them, 19 were compared between CXCT alone and Western medicine alone [14, 17–34], and 17 were CXCT combined with Western medicine compared between Western medicine alone [35–51]. The article screening process is shown in Figure 1.

2017 patients were included in the 19 articles (A). There were 1043 cases in the experimental group and 974 cases in the control group. 1292 patients were included in the 17 articles (B). There were 651 cases in the experimental group and 641 cases in the control group. The analysis of the patient's age and sex in all literature indicated there was no statistically significant difference (P>0.05). The methodology of all trials was RCT. The experimental group of study A was treated with CXCT alone, while the control group was treated with Western medicine alone. The experimental group of study B was treated with CXCT and WMC (CXCT&WMC), while the control group was treated with Western medicine alone. All of included studies used the TER as primary outcome measures and most of included studies used ARs as second outcome measure. Some articles contain indexes of serum 5-HT, β-EP, SP levels, indexes of hemorheology and VAS (Tables 1 and 2).

3.2. Quality of Included Trials Assessment. According to the Cochrane risk of bias estimation, seven studies used the random number table for grouping [14, 17, 43, 45, 47–49]. One study was randomly allocated according to the visiting sequence [30], the rest of the studies only referred to “randomization”.

One of the included studies mentioned the use of blind method or allocation concealment [43]. Therefore, performance bias and detection bias in other studies are considered to be “unclear risks”. Eleven studies mentioned the follow-up [14, 30, 39, 41, 43–46, 48, 50, 51]. There is no shortage of cases or selective reports, so the attrition bias and reporting bias were assessed as “low risk”.

3.3. Outcome Measures with Subgroup Analysis

3.3.1. The Total Efficiency of CXCT vs. WMC and CXCT& WMC vs. WMC Therapy Alone. The total effective rate was observed in 19 studies and 2017 cases in study A. The total effective rate was 90.41 (943/1043) in the experiment group and 70.02% (682/974) in the control group. Heterogeneity tests of 19 studies showed that there was no heterogeneity (Chi²=12.64; P = 0.81> 0.05; I² = 0%). Fixed-effect model analysis certified that (OR=4.31; 95% CI 3.34 to 5.56; Z=11.21 (P <0.00001)) CXCT was significantly increased the TERs compared with WMC (Figure 2).
| Study       | Diagnostic standard | Drug E/C                                                                 | Case E/C | Sex E/C | Ages E/C |
|------------|---------------------|--------------------------------------------------------------------------|----------|---------|----------|
| Hu 2018 [18] | NR                  | Chuanxiong Chatiao san 86g 200ml/day                                    | 43/43    | 23/20   | 36.83 37.57 |
| Sun 2016 [14] | ICHD-II 2004        | Chuanxiong Chatiao san 85g 200ml/day Flunarizine hydrochloride capsules 10mg/day | 60/60    | NR      | NR       |
| Wang 2015 [19] | ICHD-II/TCGNCM     | Chuanxiong Chatiao san 166g Flunarizine hydrochloride capsules 10mg/day    | 40/40    | 15/25   | 33.5 34.30 |
| Zhao 2014 [20] | CDSS                | Chuanxiong Chatiao san 105g Flunarizine hydrochloride capsules 5mg/day    | 60/60    | 44/76   | 42       |
| Liu 2014 [21] | STCMDE              | Chuanxiong Chatiao san 133g 400ml/day Flunarizine hydrochloride capsules 10mg/day | 35/30    | 10/25   | 37.5 37  |
| Wu 2014 [22] | NR                  | Chuanxiong Chatiao san 109g Flunarizine hydrochloride capsules 10g/day    | 23/23    | 5/18    | 48       |
| Yuan 2012 [23] | PN TCGNCM           | Chuanxiong Chatiao san 68g 300ml/day Flunarizine hydrochloride capsules 10mg/day | 46/40    | 14/32   | 32.58 34.46 |
| Guo 2012 [17] | ICHD-II             | Chuanxiong Chatiao san 80g Flunarizine hydrochloride capsules 10mg/day    | 60/60    | 22/38   | 52.5 55  |
| Zhang 2012 [24] | ICHD-II/STCMDE     | Chuanxiong Chatiao san 114g Flunarizine hydrochloride capsules 10mg/day    | 40/40    | 12/28   | 36.5 38.1 |
| Mao 2013 [25] | ICHD-II             | Chuanxiong Chatiao san 105g Flunarizine hydrochloride capsules 5mg/day    | 45/45    | 24/21   | 38.8 38.5 |
| Study      | Diagnostic standard | Drug E/C                                      | Case E/C | Sex E/C | Ages E/C |
|------------|---------------------|----------------------------------------------|----------|---------|----------|
| Xia 2010 [26] | DCTPIMC\ STCMDE     | Chuanxiong Chatiao san 75g                   | 42/38    | 8/34    | 9/29     | 35       | 38       |
| Fan 2010 [27] | NR                  | Chuanxiong Chatiao san 149g                   | 50/50    | 30/20   | 33/17    | NR       | NR       |
| Zhang 2017 [28] | IMTCM              | Chuanxiong Chatiao san 108g                   | 45/40    | 6/34    | 8/37     | 35.9     | 35.5     |
| Dong 2009 [29] | IHS 1988            | Chuanxiong Chatiao san 146g                   | 55/53    | 15/40   | 16/37    | 38.7     | 38.9     |
| Li 2008 [30]  | IHS 1988            | Chuanxiong Chatiao san 188g 300ml/day        | 134/134  | 61/73   | 59/75    | 34       | 34.6     |
| Zhan 2007 [31] | IHS 1988 \ TCGNCM   | Chuanxiong Chatiao san 100g                   | 60/22    | 22/38   | 9/13     | 38.2     | 37.5     |
| Zhang 2006 [32] | IHS                | Chuanxiong Chatiao san 87g                    | 32/30    | 5/27    | 6/24     | 37.96    | 36.63    |
| Fu 2004 [33]  | IHS 1988            | Chuanxiong Chatiao san                       | 138/138  | 166/110 |          | 36.4     | 36.4     |
| Shi 2002 [34] | PIM                 | Chuanxiong Chatiao san 88g 400ml/day         | 35/28    | 11/24   | 8/20     | 45.8     | 46.1     |

(b) Quality of included trials assessment

| Study      | Random method | Treatment/weeks | Withdrawal | Adverse events | follow-up | Outcome measures |
|------------|---------------|-----------------|------------|----------------|-----------|------------------|
| Sun 2016 [14] | random number table | 4              | None       | T:3           | C:6       | 12 weeks         | TER, VAS, SP, HTS, P, β-EP |
| Study            | Random method               | Treatment/weeks | Withdrawal | Adverse events | follow-up | Outcome measures                  |
|------------------|-----------------------------|-----------------|------------|----------------|-----------|-----------------------------------|
| Hu 2018 [18]     | randomized controlled       | 12              | None       | NR             | NR        | TER, VAS, AE                      |
| Wang 2015 [19]   | randomized controlled       | 2               | None       | T:1, C:3       | NR        | TER                               |
| Zhao 2014 [20]   | randomized controlled       | 4               | None       | None           | NR        | TER                               |
| Liu 2014 [21]    | randomized controlled       | 2               | None       | NR             | NR        | TER                               |
| Wu 2014 [22]     | randomized controlled       | 2               | None       | NR             | NR        | TER                               |
| Yuan 2012 [23]   | randomized controlled       | 4               | None       | None           | NR        | TER, GMP-140, TXB, Hemorheology   |
| Guo 2012 [17]    | random number table         | 2               | None       | T:3, C:7       | NR        | TER                               |
| Zhang 2012 [24]  | randomized controlled       | 4               | None       | NR             | NR        | TER                               |
| Mao 2013 [25]    | randomized controlled       | 4               | None       | None           | NR        | TER                               |
| Xia 2010 [26]    | randomized controlled       | 3               | None       | None           | NR        | TER, ABV                          |
| Fan 2010 [27]    | randomized controlled       | 2               | None       | NR             | NR        | TER                               |
| Zhang 2017 [28]  | randomized controlled       | 2               | None       | NR             | NR        | TER                               |
| Dong 2009 [29]   | randomized controlled       | 4               | None       | NR             | NR        | TER, ABV                          |
| Li 2008 [30]     | Odd even number distribution| 4               | None       | NR             | 3 months  | TER                               |
| Zhan 2007 [31]   | randomized controlled       | 4               | None       | NR             | NR        | TER                               |
| Zhang 2006 [32]  | randomized controlled       | 3               | None       | T:1, C:4       | NR        | TER                               |
| Fu 2004 [33]     | randomized controlled       | 4               | None       | T:4, C:3       | NR        | TER, TD(integral), SP, DP         |
| Shi 2002 [34]    | randomized controlled       | 4               | None       | None           | NR        | TER                               |

E, experiment group; C, control group; NR, not report.
IHSS, International Headache Society. TCGNCM, The Clinical Guidelines for the New Chinese Medicine. CDSS, Clinical Diagnosis Symptoms of Study. STCMDE, Standard of TCM Diagnosis and Efficacy. PN, Practical Neurology. DCTPIMC, Diagnostic Criteria and Treatment Points of Internal Medical Diseases. HCN, Handbook of Clinical Neurology. IMTCM, Internal Medicine of Traditional Chinese Medicine. GFDSTMC, Guidelines for diagnosis and treatment of migraine in China. HMNDT, Handbook of Modern Neurology Diagnosis and Treatment.
PIM, Practical Internal Medicine. TER, Total Efficacy Rate. ABV, average blood velocity in the brain. AT, analgesic time. HT, heal time. SP, systolic pressure. DP, diastolic pressure. SF, seizure frequency. NE, number of episodes. ND, number of days of attack.
TD, time of duration.
Table 2
(a) Basic characteristic of included studies

| Study     | Diagnostic standard | Drug E/C                                      | Case E/C | Sex E/C | Ages E/C |
|-----------|---------------------|-----------------------------------------------|----------|---------|----------|
| Zheng2009 | HCN\IMTCM           | Chuanxiong Chatiaosan 63g 400ml/day + Flunarizine hydrochloride capsules 10mg/day | 30/30    | 12/18   | 34.78    | 37.57    |
| Sun2010   | HMNDT\IMTCM         | Chuanxiong Chatiaosan 63g 400ml/day + Flunarizine hydrochloride capsules 10mg/day | 40/30    | 24/16   | 35       | 34.7     |
| Meng2011  | HMNDT\IMTCM         | Chuanxiong Chatiaosan 63g 400ml/day + Flunarizine hydrochloride capsules 10mg/day | 30/30    | 12/18   | 34.75    | 34.72    |
| Geng2011  | IHS 1988            | Chuanxiong Chatiaosan 120g + Nimodipine 90mg/day | 37/37    | 15/22   | 17/20    | 45.8     | 34.46    |
| Liu2013   | NR                  | Chuanxiong Chatiaosan 400ml + Carbamazepine Tablets 0.2g/day | 42/42    | 15/27   | 16/26    | 63.72    | 52.64    |
| Cao2014   | HMNDT\IMTCM         | Chuanxiong Chatiaosan 145g 400ml/day + Flunarizine hydrochloride capsules 10mg/day | 30/30    | NR      | NR       | NR       | NR       |
| Nie2015   | Neurology\IMTCM     | Chuanxiong Chatiaosan 100g 400ml/day + Flunarizine hydrochloride capsules 10mg/day | 58/59    | 16/42   | 15/44    | 33.07    | 33.25    |
(a) Continued.

| Study   | Diagnostic standard       | Drug                                         | Case E/C | Sex E/C | Ages E/C |
|---------|---------------------------|----------------------------------------------|----------|---------|----------|
| Sun2015 | Neurology/TCGNCM          | Chuanxiong Chaitiao san 15g 400ml/day+Flunarizine hydrochloride capsules 10mg/day | 30/30   | 8/22    | 37.25 38.17 |
| Wang2016 | ICHD-III/TCGNCM           | Chuanxiong Chaitiao san 19g 400ml/day+Flunarizine hydrochloride capsules 10mg/day | 20/20   | NR      | 18-65   |
| Yuan2017 | ICHD-II                   | Chuanxiong Chaitiao san 87g 400ml/day+Flunarizine hydrochloride capsules 120mg/day | 39/39   | 14/25   | 32      35   |
| Zhang2017 | TCGNCM                    | Chuanxiong Chaitiao san 129g 500ml/day+Nimodipine capsules 120mg/day | 63/63   | 33/30   | 48.23 48.18 |
| Liu2017  | GFDTMC                     | Chuanxiong Chaitiao san 153g 400ml/day+Flunarizine hydrochloride capsules 5mg/day | 45/45   | 16/29   | 48.53 4757 |
| Wu2017   | TCGNCM/ICHD-II            | Chuanxiong Chaitiao san 68g 500ml/day+Flunarizine hydrochloride capsules 5mg/day | 60/60   | 19/41   | 34.09 34.52 |
| Ma2018   | ICHD-II                   | Chuanxiong Chaitiao san 153g 400ml/day+Flunarizine hydrochloride capsules 5mg/day | 43/43   | 27/16   | 43.21 43.86 |
| Zuo2018  | NR                        | Chuanxiong Chaitiao san 63g 400ml/day+Flunarizine hydrochloride capsules 10mg/day | 31/31   | 13/18   | 35.2   34.8 |
| Cai2018  | DCTPIMC                   | Chuanxiong Chaitiao san 153g 400ml/day+Flunarizine hydrochloride capsules 5mg/day | 43/43   | 40/46   | 41.23  |
| Zhao2018 | DCTPIMC                   | Chuanxiong Chaitiao san 153g 400ml/day+Flunarizine hydrochloride capsules 5mg/day | 68/68   | 22/46   | 52.09 51.07 |

(b) Quality of included trials assessment

| Study    | Random method | Treatment/weeks | Withdrawal E/C | Adverse events E/C | follow-up | Outcome measures |
|----------|---------------|-----------------|----------------|-------------------|-----------|-----------------|
| Zheng2009 | randomized controlled | 4               | None           | None              | NR        | TER, ABV       |
| Sun2010  | randomized controlled | 4               | None           | None              | NR        | TER, ABV       |
| Meng2011 | randomized controlled | 4               | None           | None              | NR        | TER            |
| Study   | Random method       | Treatment/weeks | Withdrawal E/C | Adverse events E/C | follow-up | Outcome measures |
|---------|---------------------|-----------------|-----------------|---------------------|-----------|------------------|
| Geng2011 | randomized controlled | 4               | None            | None                | NR        | TER              |
| Liu2013  | randomized controlled | 4               | None            | NR                  | 6 months  | TER              |
| Cao2014  | randomized controlled | 4               | None            | NR                  | NR        | TER              |
| Nie2015  | randomized control method | 4  | None           | 2/1                 | None      | 1 months | VAS, NE, ND, TD |
| Sun2015  | randomized controlled | 4               | None            | NR                  | NR        | TER              |
| Wang2016 | random number table  | 4               | 1/2             | 1/2                 | 3 months  | TER, VAS, AT, NE |
| Yuan2017 | randomized controlled | 4               | None            | NR                  | 6 months  | TER              |
| Zhang2017 | random number table  | 4               | None            | NR                  | NR        | TER              |
| Liu2017  | randomized controlled | 4               | None            | NR                  | 1 months  | TER, VAS         |
| Wu2017   | random number table  | 4               | None            | NR                  | 6 months  | TER, VAS, PSQI   |
| Ma2018   | random number table  | 2               | None            | 4/3                 | NR        | TER              |
| Zuo2018  | randomized controlled | 6               | None            | NR                  | 6 months  | TER              |
| Cui2018  | random number table  | 8               | None            | NR                  | 3 months  | TER              |
| Zhao2018 | randomized controlled | 4               | None            | NR                  | 1 months  | TER              |

E, experiment group; C, control group; NR, not report.
IHS, International Headache Society. TCGNCM, The Clinical Guidelines for the New Chinese Medicine. CDSS, Clinical Diagnosis Symptoms of Study. STCMDE, Standard of TCM Diagnosis and Efficacy. PN, Practical Neurology. DCTPIMC, Diagnostic Criteria and Treatment Points of Internal Medical Diseases. HCN, Handbook of Clinical Neurology. IMTCM, Internal Medicine of Traditional Chinese Medicine. GFDTMC, Guidelines for diagnosis and treatment of migraine in China. HMNDT, Handbook of Modern Neurology Diagnosis and Treatment.
PIM, Practical Internal Medicine. TER, Total Efficacy Rate. ABV, average blood velocity in the brain. AT, analgesic time. HT, heal time. SP, systolic pressure. DP, diastolic pressure. SF, seizure frequency. NE, number of episodes. ND, number of days of attack. TD, time of duration.
The total effective rate was observed in 17 studies and 1292 cases in study B. The total effective rate was 91.70% (597/651) in the experiment group and 72.70% (466/641) in the control group. Heterogeneity tests of 17 studies showed that there was no heterogeneity (Chi² = 2.47; P = 1.00 > 0.05; I² = 0%). Fixed-effect model analysis certified that CXCT and WMC (OR = 4.30; 95% CI 3.09 to 6.00; Z = 8.61 (P < 0.00001)) was significantly increased the TERs compared with WMC (Figure 3).

3.3.3. Ordinary Indexes of CXCT and CXCT&WMC vs. WMC Therapy Alone. In this paper, some indexes of CXCT for migraine reported in the two studies. VAS is known as the visual analog scoring method for pain assessment and is widely used in China. The lower the VAS score, the better. Seven trails of the two studies evaluated the VAS indicator [14, 18, 41, 43, 46, 49, 51]. A fixed-effect analysis certified that CXCT and CXCT combined with WMC significantly reduced the level of VAS compared to WMC alone (WMD = -0.94; 95% CI -1.09 to -0.80, P < 0.00001; Figure 5). The experimental group and the control group were counted on the number of migraine episodes (NE) before and after treatment. The WMD with 95% CI for NE was (-1.00, 95%CI: -1.18, -0.81) certifying a significant increase in the experimental group compared to control group (P < 0.00001; Figure 6). 4 trail [41–43, 50] reported the time of headache duration (TD). The WMD with 95%CI for TD was (-2.83, 95%CI: -3.49, -2.18), indicating a significant decrease in the headache time in the experimental group compared to control group (P < 0.00001; Figure 6).

3.3.4. Blood Parameters Indexes of CXCT and CXCT&WMC vs. WMC Therapy Alone. 3 [14, 45, 48] trails provided measures of 5-HT in serum state. There has no heterogeneity
Evidence-Based Complementary and Alternative Medicine 11

Figure 3: Forest plot of the total effective rate of CXCT&WMC vs. WMC.

| Study or Subgroup | Experimental | Control | Odds Ratio | Risk of Bias |
|------------------|--------------|---------|------------|-------------|
|                  | Events | Total | Events | Total | Weight | M-H | Fixed | 95% CI | A | B | C | D | E | F | G |
| cao2014          | 26     | 30    | 18     | 30    | 6.4%   | 4.33 | [1.20, 15.61] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| cui2018          | 39     | 43    | 33     | 43    | 8.2%   | 2.95 | [0.85, 10.30] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| geng2011         | 35     | 37    | 27     | 37    | 3.9%   | 6.48 | [1.31, 32.07] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| liu2013          | 40     | 42    | 33     | 42    | 4.2%   | 5.45 | [1.10, 27.02] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| liu2017          | 42     | 45    | 37     | 45    | 6.6%   | 3.03 | [0.75, 12.26] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| ma2018           | 40     | 43    | 33     | 43    | 6.2%   | 4.04 | [1.03, 15.90] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| meng2011         | 26     | 30    | 18     | 30    | 6.4%   | 4.33 | [1.20, 15.61] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| sun2010          | 36     | 40    | 17     | 30    | 5.2%   | 6.88 | [1.95, 24.27] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| sun2015          | 28     | 30    | 22     | 30    | 3.9%   | 5.09 | [0.98, 26.43] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| wangi2016        | 17     | 20    | 11     | 20    | 4.4%   | 4.64 | [1.02, 21.00] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| wu2017           | 57     | 60    | 47     | 60    | 6.3%   | 5.26 | [1.41, 19.54] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| yuan2017         | 35     | 39    | 26     | 39    | 7.1%   | 4.38 | [1.28, 14.97] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| zhanguo2017      | 57     | 63    | 49     | 63    | 12.5%  | 2.71 | [0.97, 7.60]  | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| zhaoc2018        | 65     | 68    | 55     | 68    | 6.5%   | 5.12 | [1.39, 18.90] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| zhengc2009       | 26     | 30    | 18     | 30    | 6.4%   | 4.33 | [1.20, 15.61] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |
| zhuo2018         | 28     | 31    | 22     | 31    | 5.7%   | 3.82 | [0.92, 15.81] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] | [ ] |

Total (95% CI) 651 641 100.0% 4.30 [3.09, 6.00]

Risk of bias legend:
(A) Allocation concealment (selection bias)
(B) Blinding of participants and personnel (performance bias)
(C) Blinding of outcome assessment (detection bias)
(D) Incomplete outcome data (attrition bias)
(E) Selective reporting (reporting bias)
(F) Other bias
(G) Random sequence generation (selection bias)

in serum (P < 0.00001, I² = 0%), a fixed-effect model was thus used for analysis. The WMD and 95% CI for 5-HT was (WMD = 28.83, 95%CI: 24.24, 33.42), indicating a significant increase of 5-HT in experimental group (P = 0.89; Figure 6).

The blood parameters levels of β-EP, SP indexes were measured in two trails [14, 48], CGRP was provided in two trails [43, 45]. GMP-140 and TXB2 levels were provided in another trail [23, 52]. The WMD with 95%CI for β-EP, SP, CGRP, GMP-140 and TXB2 were (WMD=10.16; 95%CI 8.56 to 11.76), (WMD=-8.84; 95% CI -10.14 to -7.45), (WMD=-2.31;95%CI -4.01 to -0.61), (WMD=-1.22;95%CI -2.91 to 0.48) and (WMD=-8.36;95%CI -16.80 to 0.08). The results showed that the levels of β-EP were significantly increased in the experiment group in treating migraine. Besides, SP, CGRP, GMP-140, and TXB2 indexes were significantly decreased in the experiment group.

One study [23] was reported in the indexes of hemorheology, including high shear viscosity, low shear viscosity, plasma viscosity and fibrin glue. Meta-analysis showed significantly decrease in high shear viscosity (WMD=-2.31; 95%CI 8.56 to 11.76), (WMD=-8.84; 95% CI -10.14 to -7.45), (WMD=-2.31;95%CI -4.01 to -0.61), (WMD=-1.22;95%CI -2.91 to 0.48) and (WMD=-8.36;95%CI -16.80 to 0.08). The results showed that the levels of β-EP were significantly increased in the experiment group in treating migraine. Besides, SP, CGRP, GMP-140, and TXB2 indexes were significantly decreased in the experiment group.

3.4. Bias and Funnel Chart. Funnel plot can be used to directly observe the publication bias. The scattered points in the figure are basically symmetric, and there is no obvious publication bias (Figure 7).

4. Discussion

Migraine, which is also called by vasodilator headache, is a kind of familial hereditary disease. The mechanism of the disease is not entirely clear, and experts believe that it may be related to heredity, nerve, blood vessels, and others [53]. At present, there are mainly the following theories: vascular theory, neural theory, and trigeminal vascular theory. And the vasculogenic theory was first proposed. With the progress of the time, trigeminal nerve theory has been widely accepted. It was reported that migraine attacks are due to defects in the regulation of pain for trigeminal vascular system [54]. When the brain is stimulated by pain, substances of released regulatory make the cerebral blood vessels dilate, which causes migraine.

The theory of Chinese medicine believes that “Unsmooth will lead to pain”; therefore, Chinese medicine treatment of migraine is mainly improved blood circulation and pain relief. Modern pharmacological research proved migraine and platelet function (GMP-140 and TXB2) were closely related to hemorheology (high shear viscosity, low-cut viscosity, plasma viscosity, and fibrinogen). Since migraine is the result of an inflammatory mechanism mediated by serotonin signaling, leukocyte function, platelet function, and intercellular communication between these cells may be involved in the ultimate pathway of disease [55].
Figure 4: Forest plot of adverse events of medicine.

Figure 5: Forest plot of VAS of CXCT&WMC vs. WMC.
Clinical trials have shown that CXCT can reduce the duration of headaches and reduce the number of headache attacks in migraine patients. The composition of CXCT may affect the expression of CGRP and ET-1 genes which can reduce the synthesis of CGRP and ET-1, then weaken vasomotor of blood vessels which can prevent migraines [16, 17]. There is growing modern pharmacology studies revealed that *Ligusticum chuanxiong hort* has favorable pharmacological activity and effect. Main effective ingredients of *Ligusticum chuanxiong hort* are senkyunolide and ligustrazine, both of which can reduce calcium ions and other related factors and regulate the formation of NO in plasma and the brain to alleviate migraine. The mechanism of pain relief for migraine model rats may be through adjustment of monoamine neurotransmitter levels and turnover, as well as reduction of nitric oxide levels in the blood and brain. Therefore, senkyunolide
According to the research, the total coumarin extract (TCE) can reduce the content of 5-HT in the brain and blood [34]. Angelicae Dahuricae Radix may be developed as a potential treatment for migraine [52, 56–58].

I may be developed as a potential treatment for migraine [52, 56–58]. Angelicae Dahuricae Radix can significantly reduce the content of 5-HT in the brain and blood [34]. According to the research, the total coumarin extract (TCE) of Angelicae Dahuricae Radix can enhance the antimigraine activity of ligustrazine by reducing the level of head scratches, plasma calcitonin gene-related peptide, serum nitric oxide, and elevating the level of plasma endothelin (p < 0.05) [59]. Other drugs have been reported to have good adjuvant treatment for migraine. Chinese medicine prescriptions can be adjusted to the different symptoms of different patients; it helps to ensure the drug efficacy and rapid recovery. A total of 3307 patients were included in the 37 articles. In the study A, the meta-analysis showed that CXCT had better clinical efficacy than WMC in treating migraine (OR=4.31; 95% CI -10.14 to -7.45) in the experiment group was significantly lower than that of the control group. The increase of GMP-140 and TXB2 in the blood can cause vasoconstriction and aggravate the pain of migraine patients. The results showed that the indexes of GMP-140 (WMD=-1.22; 95% CI -2.91 to 0.48) and TXB2 (WMD=-8.36; 95% CI -16.80 to 0.08) in the experiment group were lower than those of the control group and had statistically significant differences.

The study suggested that some indexes of hemorheology in patients with migraine would increase significantly, which caused increased platelet viscosity [66]. Large amounts of 5-HT were released and consumed, and finally, the reflex expansion of blood vessels occurred, indirectly leading to migraine attacks. The results showed that the high shear viscosity (WMD=-2.31; 95% CI -2.55 to -2.07), low shear viscosity (WMD=-0.73; 95% CI -0.82 to -0.64), plasma viscosity (WMD=-3.91; 95% CI -4.33 to -3.49), and fibrin glue (WMD=-1.43; 95% CI -1.89 to -0.97) of the experiment group were lower than those of the control group. Here we certified that CXCT could improve by increasing the contents of 5-HT and β-EP, decreasing the levels of substance P, GMP-140, TXB2, and indexes of hemorheology.

From the above data, CXCT shows its advantages in the treatment of migraine whether used alone or in combination with WMC. There is no specific description of the blind method in the articles selected in this report, but we think that the article is rigorous, so the method of evaluating the article is judged to be “unclear”. When comparing the curative effect of Western medicine and traditional Chinese medicine, it is difficult to adopt blind method. Because the traditional Chinese medicine mostly uses the decoction, but the Western medicine uses the tablet, in the drug dosage form it is very difficult to use the blind method to implement. For doctors, the use of traditional Chinese medicine needs dialectical treatment; each patient needs a different treatment plan, resulting in the fact that the doctor has no way to make a blind diagnosis. This is the difficulty of using blind method in the comparison of traditional Chinese medicine. But the quality of the articles included in this study was relatively low, and the method description was incomplete.
so the result of the analysis would be biased. Although there are some limitations in traditional Chinese medicine due to the lack of basic research, evidence-based practices that may be effective make it an attractive treatment system for many diseases. The accuracy of meta-analysis results depends on the article selection. Therefore, the requirements for future experiments should be multicenter, large sample randomized control, and double-blind allocation hidden experiment. In order to improve the quality of the article, we should report cases of withdrawal, follow-up visits, and so on.

5. Conclusion

In conclusion, the clinical efficacy of CXCT and CXCT combined with WMC in the treatment of migraine is better than that of WCM alone. In addition, the incidence of adverse reactions of CXCT in the treatment of migraine was significantly lower than that of WCM. However, there was no significant difference in the incidence of adverse events between the two groups.

CXCT and CXCT combined with WMC treatment of migraine 5-HT and beta-EP index were significantly higher than WMC. The VAS, NE, TD, substance P, CGRP, GMP-140, and TXB2 index of the experimental group were lower than those of the control group. The results showed that the blood viscosity of the experimental group was lower than that of the control group.

After evaluating the quality of articles, it is found that most articles are of low quality, which may lead to some limitations of this study. The findings of present study are insufficient evidence given the lack of high-quality evidence. International methodologies and rigorous RCT can produce better tests for CXCT of migraine. Therefore, in order to evaluate the clinical efficacy of traditional Chinese medicine more scientifically and provide a promising development platform for the development of traditional Chinese medicine, more high-quality articles are needed to provide more reliable sources and data for meta-analysis.

The articles included in this report are published in high-quality journals. The blind method is not described in detail in the article, so the judgment in the methodology is “unclear”.

Abbreviations

CXCT: Chuanxiong Chatiao san
RCT: Randomized controlled trial
WCM: Western conventional medicine
TER: Total efficiency rate
AE: Adverse event

Data Availability

All data generated or analyzed during this study are included in this published article.

Conflicts of Interest

We declare that we have no conflicts of interest.

Authors’ Contributions

Yu Wang, Xiaofei Zhang, and Junbo Zou conceived the study; these two authors provided general guidance to the drafting of the protocol. Yu Wang and Junbo Zou drafted the protocol. Jia Tai, Yulin Liang, and Mei Wang designed the search strategy. Yu Wang, Xiaofei Zhang, and Yajun Shi drafted the manuscript. Chunli Cui and Dongyan Guo reviewed and revised the manuscript. All authors have read and approved the final version of the manuscript. Yu Wang, Xiaofei Zhang, and Junbo Zou contributed equally to this work.

Acknowledgments

This project was supported by the Key Research and Development Program of Shaanxi Province of China [grant number 2017ZDXM-SF-008]; Chinese Medicine Pharmaceutical Key Discipline of Shaanxi province [grant number 303061107]; Key research and development plan of Shaanxi province [grant number 2018SF-314]; Natural Science Foundation of China [grant number 81703720]. The authors would like to acknowledge the Key Laboratory of Basic and New Drug Research of Traditional Chinese Medicine in Shaanxi Province.

References

[1] B. S. Zhang, B. W. Li, Z. D. Qiu, and X. L. Dong, “Progress in migraine research,” Asia-Pacific Traditional Medicine, vol. 22, pp. 43–45, 2017.
[2] S. Akerman, M. Romero-Reyes, and P. R. Holland, “Current and novel insights into the neurophysiology of migraine and its implications for therapeutics,” Pharmacology & Therapeutics, vol. 172, pp. 151–170, 2017.
[3] R. B. Lipton, W. F. Stewart, S. Diamond, M. L. Diamond, and M. Reed, “Prevalence and burden of migraine in the United States: data from the American migraine study II,” Headache: The Journal of Head and Face Pain, vol. 41, no. 7, pp. 646–657, 2001.
[4] L. Mayans and A. Walling, “Acute migraine headache: treatment strategies,” Am Fam Physician, vol. 97, no. 4, pp. 243–251, 2018.
[5] H. Diener, D. Holle, T. Dresler, and C. Gaul, “Chronic headache due to overuse of analgesics and anti-migraine agents,” Deutsches Aerzteblatt Online, vol. 115, no. 22, pp. 365–370, 2018.
[6] B. A. Bauer, J. C. Tilburt, A. Sood, G.-X. Li, and S.-H. Wang, “Complementary and alternative medicine therapies for chronic pain,” Chinese Journal of Integrative Medicine, vol. 22, no. 6, pp. 403–411, 2016.
[7] G. D’Andrea, S. Cevoli, and D. Cologno, “Herbal therapy in migraine,” Neurological Sciences, vol. 35, no. 51, pp. 135–140, 2014.
[8] J. Li, X. Shen, X. Meng, Y. Zhang, and X. Lai, “Analgesic effect and mechanisms of the three TCM-herbal drug-combination Tou Feng Yu Pill on treatment of migraine,” Phytomedicine, vol. 18, no. 8–9, pp. 788–794, 2011.
Evidence-Based Complementary and Alternative Medicine

[45] P. L. Wu and Y. Q. Zhang, “Observation on the curative effect of Jiawei Chuanxiong Tea Tiaosan combined with western medicine in the treatment of migraine,” Shannxi Zhongyi, vol. 38, no. 7, pp. 859–860, 2017.

[46] Q. Yuan, D. M. Wu, and J. L. Ni, “39 cases of migraine treated with chuanxiong chatiao san and nimodipine,” Chinese Ethnic and Folk Medicine, vol. 26, no. 4, pp. 90–94, 2017.

[47] G. N. Zhang and Y. L. Xu, “63 cases of migraine treated with chuanxiong tea tiaosan,” Clinical Journal of Chinese Medicine, vol. 9, no. 16, pp. 112–113, 2017.

[48] J. L. Zuo, Q. Y. Wu, and L. Wang, “31 cases of migraine treated with chuanxiong chatiao san,” Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine, vol. 18, no. 5, pp. 100–102, 2018.

[49] J. L. Zuo, Q. Y. Wu, and L. Wang, “31 cases of migraine treated with chuanxiong chatiao san,” Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine, vol. 18, no. 5, pp. 100–102, 2018.

[50] J. Cui, “Effect of chuanxiong tea tiaosan in the treatment of migraine patients,” Journal of Family Medicine, vol. 10, article 166, 2018.

[51] P. Borgdorff and G. J. Tangelder, “Migraine: possible role of shear-induced platelet aggregation with serotonin release,” Headache: The Journal of Head and Face Pain, vol. 52, no. 8, pp. 1298–1318, 2012.

[52] A. Negro, A. Koverech, and P. Martelletti, “Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential,” Journal of Pain Research, vol. 11, pp. 515–526, 2018.

[53] A. R. Genazzani, G. Sandrini, F. Facchinetti et al., “Effects of L-5HTP with and without carbidopa on plasma beta-endorphin and pain perception: possible implications in migraine prophylaxis,” Cephalalgia, vol. 6, no. 4, pp. 241–245, 2010.

[54] A. R. Genazzani, G. Sandrini, F. Facchinetti et al., “Effects of L-5HTP with and without carbidopa on plasma beta-endorphin and pain perception: possible implications in migraine prophylaxis,” Cephalalgia, vol. 6, no. 4, pp. 241–245, 2010.

[55] J. Zeller, V. Lindner, K. Frahm, R. Baron, and G. Deuschl, “Platelet activation and platelet-leucocyte interaction in patients with migraine. subtype differences and influence of triptans,” Cephalalgia, vol. 25, no. 7, pp. 536–541, 2016.

[56] Q. Wang, L. Shen, S. Ma et al., “Determination of the levels of two types of neurotransmitter and the anti-migraine effects of different dose-ratios of ligusticum chuanxiong and gastrodia elata,” Journal of Food and Drug Analysis, vol. 24, no. 1, pp. 189–198, 2016.

[57] M. Ben Aissa, A. F. Tipton, Z. Bertels et al., “Soluble guanylyl cyclase is a critical regulator of migraine-associated pain,” Cephalalgia, vol. 38, no. 8, pp. 1471–1484, 2017.

[58] Y.-H. Wang, S. Liang, D.-S. Xu et al., “Effect and mechanism of senkyunolide i as an anti-migraine compound from Ligusticum chuanxiong,” Journal of Pharmacy and Pharmacology, vol. 63, no. 2, pp. 261–266, 2011.

[59] S. Feng, X. He, P. Zhong, J. Zhao, C. Huang, and Z. Hu, “A metabolism-based synergy for total coumarin extract of radix angelicae dahuricae and ligustrazine on migraine treatment in rats,” Molecules, vol. 23, no. 5, 2018.

[60] M. Deen, H. D. Hansen, A. Hougaard et al., “High brain serotonin levels in migraine between attacks: a 5-HT4 receptor binding PET study,” NeuroImage: Clinical, vol. 18, pp. 97–102, 2018.

[61] S. Feng, X. He, P. Zhong, J. Zhao, C. Huang, and Z. Hu, “A metabolism-based synergy for total coumarin extract of radix angelicae dahuricae and ligustrazine on migraine treatment in rats,” Molecules, vol. 23, no. 5, 2018.

[62] M. Deen, H. D. Hansen, A. Hougaard et al., “High brain serotonin levels in migraine between attacks: a 5-HT4 receptor binding PET study,” NeuroImage: Clinical, vol. 18, pp. 97–102, 2018.